Home Online Features ABK Biomedical Announces FDA IDE Stage 2 Approval for Route90, a Prospective, Multi-Center, Pivotal Study of Eye90 microspheres® in unresectable Hepatocellular Cancer
ABK Biomedical Announces FDA IDE Stage 2 Approval for Route90, a Prospective, Multi-Center, Pivotal Study of Eye90 microspheres® in unresectable Hepatocellular Cancer
Hand-out
Press Releases
ABK Biomedical Inc.  
November 19, 2024

ABK Biomedical Announces FDA IDE Stage 2 Approval for Route90, a Prospective, Multi-Center, Pivotal Study of Eye90 microspheres® in unresectable Hepatocellular Cancer

HALIFAX, NS, Nov. 19, 2024 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, has received

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social